1-6 of 6
Wytske M. van Weerden
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Darolutamide Added to Docetaxel Augments Antitumor Effect in Models of Prostate Cancer through Cell Cycle Arrest at the G1–S Transition

Stefan A.J. Buck, Annelies Van Hemelryk, Corrina de Ridder, Debra Stuurman, Sigrun Erkens-Schulze, Sem van ’t Geloof, Wilma J. Teubel, Stijn L.W. Koolen, Elena S. Martens-Uzunova, Martin E. van Royen, Ronald de Wit, Ron H.J. Mathijssen, Wytske M. van Weerden
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (5): 711–720.
https://doi.org/10.1158/1535-7163.MCT-23-0420
Published: 02 May 2024
View article titled, Darolutamide Added to Docetaxel Augments Antitumor Effect in Models of Prostate Cancer through Cell Cycle Arrest at the G<sub>1</sub>–S Transition
Open the PDF for Darolutamide Added to Docetaxel Augments Antitumor Effect in Models of Prostate Cancer through Cell Cycle Arrest at the G<sub>1</sub>–S Transition in another window
Includes: Supplementary data
Journal Articles

The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models

Florian Handle, Martin Puhr, Georg Schaefer, Nicla Lorito, Julia Hoefer, Martina Gruber, Fabian Guggenberger, Frédéric R. Santer, Rute B. Marques, Wytske M. van Weerden, Frank Claessens, Holger H.H. Erb, Zoran Culig
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2018) 17 (12): 2722–2731.
https://doi.org/10.1158/1535-7163.MCT-18-0508
Published: 03 December 2018
View article titled, The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models
Open the PDF for The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models in another window
Includes: Supplementary data
Journal Articles

Abstract C97: Beyond intratumoural steroidogenesis: abiraterone resistance mediated by AR variants and glucocorticoid receptor signalling

Jan Matthijs Moll, Johannes Hofland, Wilma Teubel, Corrina M.A. de Ridder, Anne E. Taylor, Ralph Graeser, Wiebke Arlt, Guido W. Jenster, Wytske M. van Weerden
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): C97.
https://doi.org/10.1158/1535-7163.TARG-15-C97
Published: 01 December 2015
View article titled, Abstract C97: Beyond intratumoural steroidogenesis: abiraterone resistance mediated by AR variants and glucocorticoid receptor signalling
Journal Articles

Abstract C68: SLCO1B3 influences taxane-response in prostate cancer

Ellen S. de Morree, Rene Bottcher, Robert J. van Soest, Ashraf Aghai, Corrina M. de Ridder, Alice A. Gibson, Ron HJ Mathijssen, Herman Burger, Erik AC Wiemer, Alex Sparreboom, Wytske M. van Weerden, Ronald de Wit
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): C68.
https://doi.org/10.1158/1535-7163.TARG-15-C68
Published: 01 December 2015
View article titled, Abstract C68: SLCO1B3 influences taxane-response in prostate cancer
Journal Articles

Abstract A5: Establishment of a novel spontaneous prostate cancer liver metastasis model

Stefan J. Roobol, Johanneke A.A. van Zoggel, Corrina M.A. de Ridder, Sander A.H. Hoeben, Yin C.I.L. Versluis, Yanto R. Ridwan, Joost C. Haeck, Wytske M. van Weerden
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): A5.
https://doi.org/10.1158/1535-7163.TARG-15-A5
Published: 01 December 2015
View article titled, Abstract A5: Establishment of a novel spontaneous prostate cancer liver metastasis model
Journal Articles

Abstract B185: High efficacy of combination therapy of PI3K/AKT inhibitors with androgen deprivation in prostate cancer.

Rute Marques, Ashraf Aghai, Debra Stuurman, Corrina de Ridder, Agnes Boer, Sander Hoeben, Jan Trapman, Wytske M. van Weerden
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): B185.
https://doi.org/10.1158/1535-7163.TARG-13-B185
Published: 01 November 2013
View article titled, Abstract B185: High efficacy of combination therapy of PI3K/AKT inhibitors with androgen deprivation in prostate cancer.